EANM 2025: 225Ac-SSO110 Data Supports the Advancement for ES-SCLC and MCC
“These oral presentations demonstrate Ariceum’s commitment to leading innovation in targeted radiotherapeutics,” said Germo Gericke, MD, Chief Medical Officer of Ariceum Therapeutics. “For the first time, we are presenting data showing minimal in-vivo redistribution of daughter radionuclides with 225Ac-SSO110, a non-internalizing SSTR2 antagonist, an important advance in our understanding of targeted alpha therapy. In parallel, our SANTANA-225 study showcases an innovative, first‑in-class approach for patients with ES‑SCLC and MCC. With the SANTANA-225 initial safety readout expected in 2026 and preliminary efficacy in 2027, we remain committed to setting new standards in both research and patient care for diseases with high unmet needs.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.